Cat. No.: HY-10162

Olaparib

(Synonyms: AZD2281; KU0059436)

375 Cited Publications

Avis client

Based on 375 publication(s) in Google Scholar

Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 763113-22-0
Formule: C₂₄H₂₃FN₄O₃
Masse moléculaire:434.46

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Olaparib Chemical Structure

CAS No.: 763113-22-0

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (375)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

PARP-2

1 nM (IC₅₀)

PARP-1

5 nM (IC₅₀)

tankyrase-1

1.5 μM (IC₅₀)

Autophagy

Mitophagy

Voir tous les produits spécifiques à Isoform PARP :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	1 μM Compound: Olaparib, KU-59436, AZD 2281	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 24398383]
A-375	IC₅₀	12.71 μM Compound: AZD2281	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36183505]
A549	IC₅₀	28 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
A549	IC₅₀	5.89 μM Compound: Olaparib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 35643262]
A549	IC₅₀	31.6 μM Compound: AZD2281	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36183505]
A549	IC₅₀	29.5 μM Compound: Olaparib	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	6.06 μM Compound: Olaparib	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	>200 μM Compound: A1	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
AML12	CC₅₀	31.09 μM Compound: Olaparib	Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay	[PMID: 35504210]
Bel-7402	IC₅₀	35.5 μM Compound: Olaparib	Antiproliferative activity against human Bel-7402 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 30844273]
BT-549	IC₅₀	6610 nM Compound: Olaparib	Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38039793]
BT-549	IC₅₀	35.25 μM Compound: Ola	Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
C-33-A	IC₅₀	>200 μM Compound: A1	Antiproliferative activity against human C-33-A cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human C-33-A cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
Caco-2	IC₅₀	65.5 μM Compound: Olaparib	Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 30844273]
CAPAN-1	IC₅₀	6.3 μM Compound: Olaparib, KU-59436, AZD 2281	Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay	[PMID: 24398383]
CAPAN-1	EC₅₀	259 nM Compound: 2; AZD-2281	Cytotoxicity against BRCA2-deficient human Capan1 cells Cytotoxicity against BRCA2-deficient human Capan1 cells	[PMID: 26652717]
CAPAN-1	IC₅₀	399.3 nM Compound: 1; AZD-2281	Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay	[PMID: 28692916]
CAPAN-1	IC₅₀	83.1 μM Compound: Ola	Antiproliferative activity against BRCA2-deficient human Capan1 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA2-deficient human Capan1 cells after 48 hrs by MTT assay	[PMID: 32222339]
CAPAN-1	IC₅₀	0.027 μM Compound: 5; OLA	Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 13 days by by CCK-8 assay Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 13 days by by CCK-8 assay	[PMID: 32924477]
CAPAN-1	IC₅₀	8.42 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability after 4 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 34813314]
CAPAN-1	IC₅₀	2.61 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	25.2 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	5.34 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	8.42 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
CAPAN-1	IC₅₀	0.053 μM Compound: Olaparib	Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay	[PMID: 35430559]
CAPAN-1	IC₅₀	1.67 μM Compound: Olaparib	Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability	[PMID: 35643262]
CAPAN-1	IC₅₀	0.053 μM Compound: OL	Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35780655]
CAPAN-1	IC₅₀	0.53 μM Compound: 1; AZD2281	Antiproliferative activity against BRCA2-deficient human CAPAN-1 cells assessed as inhibition of cell proliferation incubated for 7 days by CellTiter-Glo assay Antiproliferative activity against BRCA2-deficient human CAPAN-1 cells assessed as inhibition of cell proliferation incubated for 7 days by CellTiter-Glo assay	[PMID: 35785724]
CAPAN-1	IC₅₀	21410.9 nM Compound: OP	Antiproliferative activity against human Olaparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human Olaparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
CAPAN-1	IC₅₀	7582.42 nM Compound: OP	Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
CAPAN-1	IC₅₀	764 nM Compound: OP	Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
CAPAN-1	IC₅₀	60.66 μM Compound: A1	Antiproliferative activity against human CAPAN-1 cells harboring BRCA1 mutant assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human CAPAN-1 cells harboring BRCA1 mutant assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
CFPAC-1	IC₅₀	13.7 μM Compound: Olaparib	Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability after 4 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 34813314]
CFPAC-1	IC₅₀	13.7 μM Compound: Olaparib	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	28.7 μM Compound: Olaparib	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	7.44 μM Compound: Olaparib	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
CFPAC-1	IC₅₀	9.87 μM Compound: Olaparib	Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
CWR22R	IC₅₀	33.8 μM Compound: Olaparib	Growth inhibition of human 22Rv1 cells after 5 days by SRB assay Growth inhibition of human 22Rv1 cells after 5 days by SRB assay	[PMID: 32484346]
DLD-1	EC₅₀	0.1 μM Compound: 2	Antiproliferative activity against BRCA deficient human DLD1 cells by Celltiter-Glo assay Antiproliferative activity against BRCA deficient human DLD1 cells by Celltiter-Glo assay	[PMID: 31303996]
DLD-1	EC₅₀	19 μM Compound: 2	Antiproliferative activity against human DLD1 cells by Celltiter-Glo assay Antiproliferative activity against human DLD1 cells by Celltiter-Glo assay	[PMID: 31303996]
DLD-1	IC₅₀	0.042 μM Compound: 1	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
DLD-1	IC₅₀	171.8 nM Compound: Olaparib	Antiproliferative activity against human DLD-1 cells harbouring BRCA-2 mutant assessed as inhibition of cell growth Antiproliferative activity against human DLD-1 cells harbouring BRCA-2 mutant assessed as inhibition of cell growth	[PMID: 36343904]
DLD-1	IC₅₀	23.326 μM Compound: Olaparib	Antiproliferative activity against human DLD-1 cells harbouring wild type BRCA assessed as inhibition of cell growth Antiproliferative activity against human DLD-1 cells harbouring wild type BRCA assessed as inhibition of cell growth	[PMID: 36343904]
DLD-1	IC₅₀	13.72 μM Compound: Olaparib	Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36921527]
DLD-1	IC₅₀	0.401 μM Compound: 1	Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
DLD-1	IC₅₀	1.91 μM Compound: 1	Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	14.7 μM Compound: 1	Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
DLD-1	IC₅₀	2.29 μM Compound: 1	Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	25.7 μM Compound: 1	Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DLD-1	IC₅₀	26.8 μM Compound: 1	Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
DU-145	IC₅₀	17.7 μM Compound: Olaparib	Growth inhibition of human DU145 cells after 5 days by SRB assay Growth inhibition of human DU145 cells after 5 days by SRB assay	[PMID: 32484346]
DU-145	IC₅₀	11.44 μM Compound: Olaparib	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability	[PMID: 35643262]
ES-2	IC₅₀	2.05 μM Compound: Olaparib	Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
HCC1937	IC₅₀	10.3 μM Compound: Olaparib, KU-59436, AZD 2281	Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay	[PMID: 24398383]
HCC1937	IC₅₀	8.65 μM Compound: Olaparib	Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay	[PMID: 28601509]
HCC1937	IC₅₀	4.97 μM Compound: Olaparib	Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay	[PMID: 28763648]
HCC1937	IC₅₀	>200 μM Compound: Ola	Antiproliferative activity against BRCA1-deficient human HCC1937 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA1-deficient human HCC1937 cells after 48 hrs by MTT assay	[PMID: 32222339]
HCC1937	IC₅₀	>10 μM Compound: Olaparib	Antiproliferative activity against human BRCA-1 deficient HCC1937 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay Antiproliferative activity against human BRCA-1 deficient HCC1937 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay	[PMID: 33740547]
HCC1937	IC₅₀	13 μM Compound: Olaparib	Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as cell growth inhibition Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as cell growth inhibition	[PMID: 34091044]
HCC1937	IC₅₀	83.1 μM Compound: Olaparib	Antiproliferative activity against BRCA deficient human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against BRCA deficient human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34998039]
HCC1937	IC₅₀	>200 μM Compound: ola	Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
HCC1937	IC₅₀	>30 μM Compound: Olaparib	Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability	[PMID: 35643262]
HCC1937	IC₅₀	8.1 μM Compound: OP	Antiproliferative activity against HR-deficient human HCC1937 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against HR-deficient human HCC1937 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
HCC1937	IC₅₀	6510 nM Compound: Ola	Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition	[PMID: 37616488]
HCC1937	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib	[PMID: 37616488]
HCC1937	IC₅₀	38.2 μM Compound: Olaparib	Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
HCC1937	IC₅₀	22.03 μM Compound: A1	Antiproliferative activity against human HCC1937 cells harboring BRCA2 mutant assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human HCC1937 cells harboring BRCA2 mutant assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
HCC827	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 28601509]
HCT-116	IC₅₀	15.13 μM Compound: Olaparib	Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay	[PMID: 28763648]
HCT-116	IC₅₀	>10 μM Compound: Olaparib	Antiproliferative activity against human BRCA-2 deficient HCT-116 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay Antiproliferative activity against human BRCA-2 deficient HCT-116 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay	[PMID: 33740547]
HCT-116	IC₅₀	5.86 μM Compound: Olaparib	Antiproliferative activity against BRCA2-deficient human HCT116 cells assessed as cell growth inhibition Antiproliferative activity against BRCA2-deficient human HCT116 cells assessed as cell growth inhibition	[PMID: 34091044]
HCT-116	IC₅₀	7.32 μM Compound: Olaparib	Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
HCT-116	IC₅₀	5.56 μM Compound: Olaparib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay	[PMID: 35504210]
HCT-116	IC₅₀	27.26 μM Compound: AZD2281	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36183505]
HCT-116	IC₅₀	26.4 μM Compound: Olaparib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36921527]
HCT-116	IC₅₀	9 μM Compound: Olaparib	Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 37406384]
HCT-116	IC₅₀	1.429 μM Compound: 1	Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
HCT-116	IC₅₀	1.81 μM Compound: 1	Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis	[PMID: 37484567]
HCT-116	IC₅₀	2.28 μM Compound: 1	Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition	[PMID: 37484567]
HCT-116	IC₅₀	2.65 μM Compound: 1	Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by	[PMID: 37484567]
HCT-116	IC₅₀	1.37 μM Compound: Olaparib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	11.13 μM Compound: Olaparib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	15.3 μM Compound: Olaparib	Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
HCT-116	IC₅₀	>200 μM Compound: A1	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
HCT-15	IC₅₀	32.08 μM Compound: OP	Antiproliferative activity against HR-deficient human HCT-15 cells harboring BRCA2 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against HR-deficient human HCT-15 cells harboring BRCA2 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
HeLa	EC₅₀	2.5 nM Compound: Olaparib, KU-59436, AZD 2281	Inhibition of PARP-1 in human HeLa cells assessed as decrease of H2O2-induced PARylation after 3 hrs by fluorescence assay Inhibition of PARP-1 in human HeLa cells assessed as decrease of H2O2-induced PARylation after 3 hrs by fluorescence assay	[PMID: 24398383]
HeLa	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28601509]
HeLa	IC₅₀	27.66 μM Compound: AZD2281	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36183505]
HeLa	IC₅₀	30.48 μM Compound: A1	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
HepG2	IC₅₀	42.4 μM Compound: Olaparib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 30844273]
HUVEC	IC₅₀	4.6 μM Compound: Ola	Inhibition of cell survival in VEGF165-treated HUVEC cells incubated for 48 hrs in presence of Pazopanib by CCK8 assay Inhibition of cell survival in VEGF165-treated HUVEC cells incubated for 48 hrs in presence of Pazopanib by CCK8 assay	[PMID: 37616488]
HUVEC	IC₅₀	>100 μM Compound: Olaparib	Inhibition of cell proliferation in HUVECs Inhibition of cell proliferation in HUVECs	[PMID: 38678823]
Jurkat	EC₅₀	0.06 μM Compound: AZD-2281	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide	[PMID: 23850199]
Jurkat	EC₅₀	16 μM Compound: AZD-2281	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay	[PMID: 23850199]
K562	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28601509]
L02	IC₅₀	25.8 μM Compound: Olaparib	Cytotoxicity against human HL7702 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 30844273]
L02	IC₅₀	60.67 μM Compound: AZD2281	Antiproliferative activity against human L02 cells assessed as inhibition of cell growth at 20 uM incubated for 48 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as inhibition of cell growth at 20 uM incubated for 48 hrs by MTT assay	[PMID: 36183505]
LoVo	EC₅₀	3.57 nM Compound: 2; AZD-2281	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
LoVo	GI₅₀	237 nM Compound: 2; AZD-2281	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
MCF-10A	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF-10A	IC₅₀	>1000 μM Compound: Olaparib	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	>1000 μM Compound: Olaparib	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	>40 μM Compound: Ola	Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
MCF-10A	IC₅₀	>80 μM Compound: Olaparib	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
MCF7	IC₅₀	35.24 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF7	IC₅₀	36.24 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28763648]
MCF7	IC₅₀	>40 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells incubated for 2 to 5 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 to 5 days by MTT assay	[PMID: 31153806]
MCF7	GI₅₀	13.2 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 32088129]
MCF7	IC₅₀	>200 μM Compound: Ola	Antiproliferative activity against BRCA-proficient human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA-proficient human MCF7 cells after 48 hrs by MTT assay	[PMID: 32222339]
MCF7	IC₅₀	232 μM Compound: Olaparib	Antiproliferative activity against BRCA proficient human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against BRCA proficient human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34998039]
MCF7	IC₅₀	409.1 μM Compound: ola	Cytotoxicity against human MCF7 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
MCF7	IC₅₀	>50 μM Compound: 16	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 35531606]
MCF7	IC₅₀	18.601 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
MCF7	IC₅₀	<1000 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF7	IC₅₀	>1000 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF7	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib	[PMID: 37616488]
MCF7	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 37616488]
MCF7	IC₅₀	2.33 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	93.87 μM Compound: Olaparib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	10580 nM Compound: Olaparib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38039793]
MCF7	IC₅₀	>100 μM Compound: Olaparib	Inhibition of cell proliferation in human MCF7 cells Inhibition of cell proliferation in human MCF7 cells	[PMID: 38678823]
MCF7	IC₅₀	3.2 μM Compound: Olaparib	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis	[PMID: 38838546]
MDA-MB-231	IC₅₀	39.51 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	7.92 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	>40 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells incubated for 2 to 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 2 to 5 days by MTT assay	[PMID: 31153806]
MDA-MB-231	GI₅₀	4.23 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay	[PMID: 32088129]
MDA-MB-231	IC₅₀	>200 μM Compound: Ola	Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 32222339]
MDA-MB-231	IC₅₀	32.36 μM Compound: Olaparib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 96 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 96 hrs by CCK8 assay	[PMID: 32726747]
MDA-MB-231	IC₅₀	62.5 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	>10 μM Compound: Olaparib	Antiproliferative activity against human BRCA proficient MDA-MB-231 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay Antiproliferative activity against human BRCA proficient MDA-MB-231 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay	[PMID: 33740547]
MDA-MB-231	IC₅₀	8.48 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 7 days Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 7 days	[PMID: 34813314]
MDA-MB-231	IC₅₀	8.48 μM Compound: Olaparib	Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
MDA-MB-231	IC₅₀	>200 μM Compound: ola	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
MDA-MB-231	IC₅₀	4.47 μM Compound: Olaparib	Antiproliferative activity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay Antiproliferative activity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay	[PMID: 35430559]
MDA-MB-231	IC₅₀	5.35 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay	[PMID: 35504210]
MDA-MB-231	IC₅₀	0.69 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
MDA-MB-231	IC₅₀	4.47 μM Compound: OL	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35780655]
MDA-MB-231	IC₅₀	24.84 μM Compound: AZD2281	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36183505]
MDA-MB-231	IC₅₀	73.31 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
MDA-MB-231	IC₅₀	<1000 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MDA-MB-231	IC₅₀	0.8 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]
MDA-MB-231	IC₅₀	1.7 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-231	IC₅₀	3.5 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37478560]
MDA-MB-231	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib	[PMID: 37616488]
MDA-MB-231	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 37616488]
MDA-MB-231	IC₅₀	>50 μM Compound: HY-10162	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37837671]
MDA-MB-231	IC₅₀	>30000 nM Compound: Olaparib	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38039793]
MDA-MB-231	IC₅₀	35.76 μM Compound: Ola	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
MDA-MB-231	IC₅₀	30.7 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-231 cells harboring wild type BRCA and c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells harboring wild type BRCA and c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay	[PMID: 38477575]
MDA-MB-231	IC₅₀	70.2 μM Compound: Olaparib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis	[PMID: 38838546]
MDA-MB-436	CC₅₀	43.2 nM Compound: 3, AZD2281	Cytotoxicity against human BRCA1-deficient MDA-MB-436 cells assessed as growth inhibition Cytotoxicity against human BRCA1-deficient MDA-MB-436 cells assessed as growth inhibition	[PMID: 23473053]
MDA-MB-436	CC₅₀	0.0169 μM Compound: AZD2281	Cytotoxicity against BRCA1-deficient human MDA-MB-436 cells by sulforhodamine B assay Cytotoxicity against BRCA1-deficient human MDA-MB-436 cells by sulforhodamine B assay	[PMID: 24815508]
MDA-MB-436	IC₅₀	39.3 nM Compound: 1; AZD-2281	Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay	[PMID: 28692916]
MDA-MB-436	IC₅₀	0.22 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-436 cells harboring BRCA1 mutation incubated for 2 to 5 days by MTT assay Antiproliferative activity against human MDA-MB-436 cells harboring BRCA1 mutation incubated for 2 to 5 days by MTT assay	[PMID: 31153806]
MDA-MB-436	IC₅₀	0.018 μM Compound: 5; OLA	Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 7 days by CCK-8 assay Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 7 days by CCK-8 assay	[PMID: 32924477]
MDA-MB-436	CC₅₀	11.38 nM Compound: AZD2281	Antiproliferative activity against BRCA1 deficient human MDA-MB-436 cells Antiproliferative activity against BRCA1 deficient human MDA-MB-436 cells	[PMID: 33246105]
MDA-MB-436	IC₅₀	0.02 μM Compound: Olaparib	Antiproliferative activity against human BRCA1 -/- MDA-MB-436 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay Antiproliferative activity against human BRCA1 -/- MDA-MB-436 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay	[PMID: 35430559]
MDA-MB-436	IC₅₀	0.02 μM Compound: OL	Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35780655]
MDA-MB-436	IC₅₀	0.1 μM Compound: 1; AZD2281	Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 7 days by CCK-8 assay Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 7 days by CCK-8 assay	[PMID: 35785724]
MDA-MB-436	IC₅₀	0.7 μM Compound: 1	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]
MDA-MB-436	IC₅₀	1.5 μM Compound: 1	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-436	IC₅₀	4.6 μM Compound: 1	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37478560]
MDA-MB-436	IC₅₀	43.2 nM Compound: 1	Antiproliferative activity against human MDA-MB-436 BRCA1-/- cells assessed as inhibition of cell growth incubated for 7 days by CCK-8 assay Antiproliferative activity against human MDA-MB-436 BRCA1-/- cells assessed as inhibition of cell growth incubated for 7 days by CCK-8 assay	[PMID: 37567056]
MDA-MB-436	IC₅₀	0.029 μM Compound: OP	Antiproliferative activity against HR-deficient human MDA-MB-436 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against HR-deficient human MDA-MB-436 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]
MDA-MB-436	IC₅₀	>10000 nM Compound: Ola	Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib	[PMID: 37616488]
MDA-MB-436	IC₅₀	9 μM Compound: Ola	Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition	[PMID: 37616488]
MDA-MB-436	IC₅₀	13.3 μM Compound: Olaparib	Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
MDA-MB-436	IC₅₀	23.89 μM Compound: Olaparib	Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect	[PMID: 38678823]
MDA-MB-436	IC₅₀	8.9 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-436 cells Antiproliferative activity against human MDA-MB-436 cells	[PMID: 38838546]
MDA-MB-468	IC₅₀	10.1 μM Compound: Olaparib	Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 33200929]
MDA-MB-468	IC₅₀	13.72 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay	[PMID: 33309164]
MDA-MB-468	IC₅₀	>10 μM Compound: Olaparib	Antiproliferative activity against human BRCA proficient MDA-MB-468 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay Antiproliferative activity against human BRCA proficient MDA-MB-468 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay	[PMID: 33740547]
MDA-MB-468	IC₅₀	1.83 μM Compound: Olaparib	Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
MDA-MB-468	IC₅₀	200 μM Compound: ola	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
MDA-MB-468	IC₅₀	4.19 μM Compound: Olaparib	Antiproliferative activity against human PTEN -/- MDA-MB-468 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay Antiproliferative activity against human PTEN -/- MDA-MB-468 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay	[PMID: 35430559]
MDA-MB-468	IC₅₀	2.52 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay	[PMID: 35504210]
MDA-MB-468	IC₅₀	35.57 μM Compound: 16	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 35531606]
MDA-MB-468	IC₅₀	4.19 μM Compound: OL	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35780655]
MDA-MB-468	IC₅₀	0.6 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37478560]
MDA-MB-468	IC₅₀	1.4 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37478560]
MDA-MB-468	IC₅₀	3.4 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37478560]
MDA-MB-468	IC₅₀	9.23 μM Compound: Olaparib	Antiproliferative activity against human MDA-MB-468 cells harboring wild type BRCA1/2, HR-proficient and non-c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay Antiproliferative activity against human MDA-MB-468 cells harboring wild type BRCA1/2, HR-proficient and non-c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay	[PMID: 38477575]
MEF	EC₅₀	14.6 μM Compound: AZD2281	Cytotoxicity against mouse wild type MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay Cytotoxicity against mouse wild type MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay	[PMID: 29856625]
MEF	EC₅₀	49.6 μM Compound: AZD2281	Cytotoxicity against mouse PARP1 deficient MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay Cytotoxicity against mouse PARP1 deficient MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay	[PMID: 29856625]
MEF	EC₅₀	8.5 μM Compound: AZD2281	Cytotoxicity against mouse PARP2 deficient MEF cells expressing PARP1 assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay Cytotoxicity against mouse PARP2 deficient MEF cells expressing PARP1 assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay	[PMID: 29856625]
MIA PaCa-2	IC₅₀	8 μM Compound: Olaparib	Cytotoxicity against human MIA PaCa-2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells incubated for 72 hrs by MTT assay	[PMID: 37406384]
MRC5	EC₅₀	5.83 μM Compound: 2; AZD-2281	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 26652717]
MV4-11	IC₅₀	13.37 μM Compound: Olaparib	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	2.36 μM Compound: Olaparib	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay	[PMID: 37832229]
MX1	EC₅₀	23.2 nM Compound: 2; AZD-2281	Cytotoxicity against BRCA1-deficient human MX1 cells Cytotoxicity against BRCA1-deficient human MX1 cells	[PMID: 26652717]
MX1	IC₅₀	35.8 μM Compound: Ola	Antiproliferative activity against BRCA1-deficient human MX1 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA1-deficient human MX1 cells after 48 hrs by MTT assay	[PMID: 32222339]
MX1	IC₅₀	35.8 μM Compound: ola	Cytotoxicity against human MX1 cells harbouring BRCA1 mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MX1 cells harbouring BRCA1 mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
MX1	IC₅₀	8.26 nM Compound: AZD2281	Cytotoxicity against human MX1 cells harbouring BRCA1 and BRCA2 assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MX1 cells harbouring BRCA1 and BRCA2 assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37843892]
NCI-H1299	IC₅₀	35.93 μM Compound: Cpd P	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34038131]
NCI-H1355	IC₅₀	33 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H1355 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H1355 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H1693	IC₅₀	19 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H1703	IC₅₀	20 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H1792	IC₅₀	16 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H1792 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H1792 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H1944	IC₅₀	25 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H1944 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H1944 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H2030	IC₅₀	34 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H2030 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H2030 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H2122	IC₅₀	38 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H2122 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H2122 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H23	IC₅₀	10 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human H23 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human H23 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H322M	IC₅₀	50 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human NCI-H322M cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human NCI-H322M cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H441	IC₅₀	28 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human H441 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human H441 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCI-H460	IC₅₀	12 μM Compound: 1, AZD2281, KU0059436	In vitro antiproliferative activity against human H460 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay In vitro antiproliferative activity against human H460 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24521039]
NCM460	IC₅₀	318.93 μM Compound: Olaparib	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36921527]
NCM460	IC₅₀	20.18 μM Compound: Olaparib	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	67.15 μM Compound: Olaparib	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	>200 μM Compound: A1	Cytotoxicity against human NCM460 cells assessed as inhibition of cell proliferation incubated for 72 hrs Cytotoxicity against human NCM460 cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
OCI-LY19	GI₅₀	0.849 μM Compound: Olaparib	Cytotoxicity against human OCI-LY19 assessed as growth inhibition after 3 days by Alamar Blue assay Cytotoxicity against human OCI-LY19 assessed as growth inhibition after 3 days by Alamar Blue assay	[PMID: 26546219]
PANC-1	IC₅₀	7 μM Compound: Olaparib	Cytotoxicity against human PANC-1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells incubated for 72 hrs by MTT assay	[PMID: 37406384]
PC-3	IC₅₀	20.6 μM Compound: Olaparib	Growth inhibition of human PC3 cells after 5 days by SRB assay Growth inhibition of human PC3 cells after 5 days by SRB assay	[PMID: 32484346]
PEO1	IC₅₀	6.4 nM Compound: Chemical probe: Olaparib	Inhibition of colony formation in human PEO1 cells incubated for 12 days by crystal violet staining based analysis Inhibition of colony formation in human PEO1 cells incubated for 12 days by crystal violet staining based analysis	[PMID: 31775874]
Raji	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human Raji cells after 3 days by MTT assay Antiproliferative activity against human Raji cells after 3 days by MTT assay	[PMID: 28601509]
Sf9	IC₅₀	0.001 μM Compound: Olaparib	Inhibition of full length human PARP1 expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay Inhibition of full length human PARP1 expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay	[PMID: 26546219]
Sf9	IC₅₀	0.003 μM Compound: Olaparib	Inhibition of human PARP2 (2 to 583 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay Inhibition of human PARP2 (2 to 583 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay	[PMID: 26546219]
Sf9	IC₅₀	1.7 μM Compound: Olaparib	Inhibition of human TNKS2 (667 to 1166 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay Inhibition of human TNKS2 (667 to 1166 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay	[PMID: 26546219]
Sf9	IC₅₀	1.8 μM Compound: Olaparib	Inhibition of full length human PARP6 expressed in a Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay Inhibition of full length human PARP6 expressed in a Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay	[PMID: 26546219]
Sf9	IC₅₀	1.9 μM Compound: Olaparib	Inhibition of human TNKS1 (1001 to 1327 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay Inhibition of human TNKS1 (1001 to 1327 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay	[PMID: 26546219]
Sf9	IC₅₀	0.5 nM Compound: Ola	Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Sf9	IC₅₀	1.2 nM Compound: Ola	Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Sf9	IC₅₀	0.036 μM Compound: Olaparib	Inhibition of recombinant human full length C-terminal His-tagged PARP1 expressed in Sf9 insect cells preincubated for 15 mins followed by NAD+ addition and measured after 40 mins by fluorescence based assay Inhibition of recombinant human full length C-terminal His-tagged PARP1 expressed in Sf9 insect cells preincubated for 15 mins followed by NAD+ addition and measured after 40 mins by fluorescence based assay	[PMID: 31153806]
Sf9	IC₅₀	0.139 μM Compound: AZD-2281	Inhibition of N-terminal GST-tagged human PARP1 expressed in a Baculovirus infected Sf9 insect cells using biotinylated substrate incubated for 1 hr by colorimetric method Inhibition of N-terminal GST-tagged human PARP1 expressed in a Baculovirus infected Sf9 insect cells using biotinylated substrate incubated for 1 hr by colorimetric method	[PMID: 31401008]
Sf9	IC₅₀	1.8 nM Compound: Olaparib	Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis	[PMID: 31442685]
Sf9	IC₅₀	1.8 x 10^-3 μM Compound: Olaparib	Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis	[PMID: 31442685]
SiHa	IC₅₀	>200 μM Compound: A1	Antiproliferative activity against human SiHa cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human SiHa cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
SK-BR-3	IC₅₀	232 μM Compound: Ola	Antiproliferative activity against BRCA-proficient human SKBR3 cells after 48 hrs by MTT assay Antiproliferative activity against BRCA-proficient human SKBR3 cells after 48 hrs by MTT assay	[PMID: 32222339]
SK-BR-3	IC₅₀	232 μM Compound: ola	Cytotoxicity against human SK-BR-3 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35393219]
SK-BR-3	IC₅₀	<1000 μM Compound: Olaparib	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
SK-OV-3	IC₅₀	1910 μM Compound: 3, AZD2281	Cytotoxicity against human SKOV3 cells after 7 days by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 7 days by sulforhodamine B assay	[PMID: 23473053]
SK-OV-3	IC₅₀	20.9 nM Compound: 3, AZD2281	Inhibition of PARP1/PARP2 in human SKOV3 cells assessed as reduction in H2O2-induced PARylation incubated for 4 hrs prior to H2O2 treatment Inhibition of PARP1/PARP2 in human SKOV3 cells assessed as reduction in H2O2-induced PARylation incubated for 4 hrs prior to H2O2 treatment	[PMID: 23473053]
SK-OV-3	IC₅₀	3.15 μM Compound: Olaparib	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 30844273]
SK-OV-3	IC₅₀	27.13 μM Compound: Olaparib	Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
SK-OV-3	IC₅₀	166.9 μM Compound: A1	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs	[PMID: 38776379]
SUM149PT	EC₅₀	0.4 μM Compound: Ola	Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis	[PMID: 31042381]
SUM149PT	EC₅₀	7 μM Compound: Ola	Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis	[PMID: 31042381]
SW1990	IC₅₀	5.73 μM Compound: Olaparib	Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability after 4 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 34813314]
SW1990	IC₅₀	19.4 μM Compound: Olaparib	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	3.63 μM Compound: Olaparib	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	4.93 μM Compound: Olaparib	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay	[PMID: 35091172]
SW1990	IC₅₀	5.73 μM Compound: Olaparib	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay	[PMID: 35091172]
SW48	IC₅₀	4.6 μM Compound: Olaparib	Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
SW480	IC₅₀	39.3 μM Compound: Olaparib	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36921527]
SW-620	IC₅₀	6 nM Compound: 47, KU0059436, AZD-2281	Ex vivo inhibition of PARP1 in human SW620 cells assessed as amount of poly(ADP-ribose) by whole cell assay Ex vivo inhibition of PARP1 in human SW620 cells assessed as amount of poly(ADP-ribose) by whole cell assay	[PMID: 18800822]
SW-620	IC₅₀	>10 μM Compound: Olaparib	Antiproliferative activity against human BRCA-2 proficient SW-620 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay Antiproliferative activity against human BRCA-2 proficient SW-620 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay	[PMID: 33740547]
SW-620	IC₅₀	6 nM Compound: 28	Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth	[PMID: 36155354]
T47D	IC₅₀	>50 μM Compound: Olaparib	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 28601509]
T98G	IC₅₀	1.6 nM Compound: 1	Inhibition of PARP1 in human T98G cells incubated for 60 mins by immunofluorescence assay Inhibition of PARP1 in human T98G cells incubated for 60 mins by immunofluorescence assay	[PMID: 26469301]
THP-1	IC₅₀	32.3 μM Compound: Olaparib	Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay	[PMID: 35091172]
U-937	IC₅₀	21.81 μM Compound: Olaparib	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28601509]
V79	CC₅₀	>10 μM Compound: 3, AZD2281	Cytotoxicity against Chinese hamster V79 cells expressing wild type BRCA2 assessed as growth inhibition Cytotoxicity against Chinese hamster V79 cells expressing wild type BRCA2 assessed as growth inhibition	[PMID: 23473053]
V79	CC₅₀	8.985 μM Compound: AZD2281	Cytotoxicity against Chinese hamster V79 cells by sulforhodamine B assay Cytotoxicity against Chinese hamster V79 cells by sulforhodamine B assay	[PMID: 24815508]
V79	IC₅₀	≥10 μM Compound: 1; AZD-2281	Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay	[PMID: 28692916]
V79	IC₅₀	4.76 μM Compound: OP	Antiproliferative activity against Chinese hamster V79 cells harboring wild type BRCA2 assessed as cell proliferation inhibition incubated for 7 days by SRB assay Antiproliferative activity against Chinese hamster V79 cells harboring wild type BRCA2 assessed as cell proliferation inhibition incubated for 7 days by SRB assay	[PMID: 37605459]

In Vitro

Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC₅₀ for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30 100 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with NSC 362856 (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out^[1]. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib(50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 763113-22-0
Appearance Solid
Masse moléculaire 434.46
Formule C₂₄H₂₃FN₄O₃
Color White to yellow
SMILES

O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
Synonyms

AZD2281; KU0059436
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (375)

All Flow CytometryBio/Physico-chemical AssayWBRT-PCRCell Proliferation/Viability Assay2D/3D Cell Culture and DifferentiationIHCGel ElectrophoresisIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors. [Abstract]

2023 May 10;8(1):183. PMID: 37160887

Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]

Cells were treated with indicated concentrations of olaparib (50-200 μM) for 6 h, and the levels of 47 S pre-rRNA were determined by qRT-PCR to assess the extent of ribosomal stress.

Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]

Cell viability assay was performed for Olaparib treated ovarian cancer organoids with/without pretreatment with the listed drugs.
Signal Transduct Target Ther

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]

2021 Apr 24;6(1):165. PMID: 33895786
Nature

Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. [Abstract]

2018 Nov;563(7729):131-136. PMID: 30356214
Cancer Cell

Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. [Abstract]

2020 Dec 14;38(6):844-856.e7. PMID: 33186520
Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Cell

Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism. [Abstract]

2025 Apr 3;188(7):1828-1841.e15. PMID: 39952247
Cell

UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. [Abstract]

2019 Jan 24;176(3):505-519.e22. PMID: 30612738
J Hematol Oncol

SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. [Abstract]

2019 Feb 8;12(1):14. PMID: 30736840
Mol Cancer

ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma. [Abstract]

2025 Oct 21;24(1):263. PMID: 41121283
Cancer Discov

BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. [Abstract]

2024 Aug 2;14(8):1476-1495. PMID: 38552003

Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495. [Abstract]

Cell viability in control or BRCA1-reconstituted UWB1.289 cells treated with PARPi (olaparib or niraparib, 42 hours) and/or RSL3 (18 hours).

Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495. [Abstract]

Cell viability in BRCA1-sgRNA–infected or control HS578T cells treated with olaparib (42 hours) and/or RSL3 (18 hours).
Cancer Discov

PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. [Abstract]

2020 Nov;10(11):1742-1757. PMID: 32669286
Cancer Discov

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. [Abstract]

2018 Mar;8(3):354-369. PMID: 29203461
Cancer Discov

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]

2017 Sep;7(9):984-998. PMID: 28588062
Nat Cancer

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. [Abstract]

2021 Jun;2(6):598-610. PMID: 34179826
Blood

Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. [Abstract]

2023 Dec 21;142(25):2175-2191. PMID: 37756525
Drug Resist Updat

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]

2026 Jan:84:101319. PMID: 41192279
Drug Resist Updat

Centromere protein U mediates the ubiquitination and degradation of RPS3 to facilitate temozolomide resistance in glioblastoma. [Abstract]

2025 May:80:101214. PMID: 40023134
Drug Resist Updat

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer. [Abstract]

2024 Sep 12:77:101151. PMID: 39395328

Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

Olaparib (1-3 μM) significantly inhibits the viability of sensitive cells (A2780) but exhibits reduced efficacy against resistant cells (A2780-OlaR), with IC₅₀ values of 5.362 μM and 168.251 μM, respectively, for A2780 and A2780-OlaR cells.

Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

Olaparib (10 μM) significantly induces DNA damage in sensitive cells (A2780).

Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

Olaparib (10 μM; 2-4 h) significantly induces DNA damage in sensitive cells (A2780).
Cancer Res

Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. [Abstract]

2025 Oct 1. PMID: 41032740
Cancer Res

Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells. [Abstract]

2025 Aug 1;85(15):2890-2904. PMID: 40327605
Cancer Res

SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]

2025 May 14. PMID: 40366633
Mol Cell

Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS. [Abstract]

2022 Jun 2;82(11):2032-2049.e7. PMID: 35460603
Cancer Res

2020;80(16 Suppl):Abstract nr 5336.
Cancer Res

2020 Aug.
Cancer Res

2020 Aug.
Mol Cell

C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation of MRE11/RAD50/NBS1 Complex. [Abstract]

2019 Sep 19;75(6):1299-1314.e6. PMID: 31353207
ACS Nano

Active Learning-Based Prediction of Drug Combination Efficacy. [Abstract]

2025 May 13;19(18):17929-17940. PMID: 40304271
Nat Commun

Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities. [Abstract]

2026 Jun 17;17(1):5361. PMID: 42310314
Nat Commun

All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. [Abstract]

2026 May 11. PMID: 42115161
Nat Commun

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [Abstract]

2026 Feb 25;17(1):3142. PMID: 41735312
Nat Commun

EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection. [Abstract]

2025 Dec 7. PMID: 41354653
Nat Commun

Refined DNA repair manipulation enables a universal knock-in strategy in mouse embryos. [Abstract]

2025 Jul 15;16(1):6502. PMID: 40664653
Nat Commun

Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. [Abstract]

2025 May 23;16(1):4793. PMID: 40410143
Nat Commun

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. [Abstract]

2024 Nov 12;15(1):9515. PMID: 39532854
Nat Commun

Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. [Abstract]

2023 Nov 2;14(1):6997. PMID: 37914699
Nat Commun

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. [Abstract]

2022 May 31;13(1):3022. PMID: 35641483
Nat Commun

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. [Abstract]

2019 Jul 2;10(1):2910. PMID: 31266951
Acta Pharm Sin B

The cytoskeletal protein smoothelin maintains homologous recombination repair by stabilizing RAD51 in an HUWE1-dependent manner in colorectal cancer. [Abstract]

2025 Dec;15(12):6444-6460. PMID: 41477349
Sci Transl Med

Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. [Abstract]

2024 Jan 3;16(728):eadg7740. PMID: 38170790
Sci Transl Med

Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. [Abstract]

2021 May 26;13(595):eabe8226. PMID: 34039740
J Extracell Vesicles

DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High-Grade Serous Ovarian Carcinoma. [Abstract]

2026 May;15(5):e70308. PMID: 42139280
Adv Sci (Weinh)

Interferon-Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple-Negative Breast Cancer. [Abstract]

2025 Nov 19:e05787. PMID: 41255229
Adv Sci (Weinh)

3-D Sustained-Release Culture Carrier Alleviates Rat Intervertebral Disc Degeneration by Targeting STING in Transplanted Skeletal Stem Cells. [Abstract]

2025 Apr;12(15):e2410151. PMID: 39985222
Adv Sci (Weinh)

Intestine-Decipher Engineered Capsules Protect Against Sepsis-induced Intestinal Injury via Broad-spectrum Anti-inflammation and Parthanatos Inhibition. [Abstract]

2025 Jan 21:e2412799. PMID: 39836501
Adv Sci (Weinh)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer. [Abstract]

2024 Jul 8:e2400140. PMID: 38973255
Adv Sci (Weinh)

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer. [Abstract]

2023 Nov;10(31):e2304638. PMID: 37702443
Nat Chem Biol

The PARP1-EXD2 axis orchestrates R-loop resolution to safeguard genome stability. [Abstract]

2025 Jun 27. PMID: 40579572
Nat Chem Biol

Synergistic protection of nascent DNA at stalled forks by MSANTD4 and BRCA1/2-RAD51. [Abstract]

2025 Aug;21(8):1182-1193. PMID: 39809895
Theranostics

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]

2020 Jul 25;10(21):9477-9494. PMID: 32863940
Nucleic Acids Res

The RNA-binding motif protein 14 regulates telomere integrity at the interface of TERRA and telomeric R-loops. [Abstract]

2023 Dec 11;51(22):12242-12260. PMID: 37930826

Olaparib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2023 Dec 11;51(22):12242-12260. [Abstract]

Dot blot analysis of telomere DNA contents in the indicated ChIP and input from U2OS cells treated with either 1 μM Olaparib (OLP) or 2 μM STL127705 (STL) for 24 h.
Biomaterials

Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. [Abstract]

2022 Oct:289:121783. PMID: 36084486
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

PARP-1 as a novel target in endocrine-resistant breast cancer. [Abstract]

2025 Jun 16;44(1):175. PMID: 40518539
J Exp Clin Cancer Res

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. [Abstract]

2023 Oct 7;42(1):260. PMID: 37803448
J Exp Clin Cancer Res

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]

2023 Aug 21;42(1):214. PMID: 37599362
J Exp Clin Cancer Res

Targeting homologous recombination deficiency in uterine leiomyosarcoma. [Abstract]

2023 May 4;42(1):112. PMID: 37143137
J Nanobiotechnology

SIRT5-modified human umbilical cord mesenchymal stem cells loaded with antioxidant polydopamine nanozyme enhance parpi resistance in ovarian cancer via fatty acid metabolism reprogramming. [Abstract]

2025 Jul 4;23(1):485. PMID: 40616128
J Nanobiotechnology

Lyophilized apoptotic vesicles restore DNA damage and mitochondria dysfunction to ameliorate radiation enteritis. [Abstract]

2025 Jul 16;23(1):521. PMID: 40671132
J Nanobiotechnology

A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer. [Abstract]

2021 Sep 4;19(1):261. PMID: 34481495
Sci Adv

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]

2026 Jun 26;12(26):eadz3351. PMID: 42361179
Sci Adv

Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer. [Abstract]

2025 Oct 10;11(41):eadw7989. PMID: 41071892
Sci Adv

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. [Abstract]

Sci Adv. 2025 Apr 25;11(17):eadu0847. PMID: 40267193
J Biomed Sci

Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors. [Abstract]

2019 Feb 4;26(1):14. PMID: 30717758

Olaparib purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2019 Feb 4;26(1):14. [Abstract]

Inhibition of NFBD1 results in defective γ-H2AX foci formation after Olaparib exposure, cells are exposed to Olaparib for 24 h, and the γ-H2AX positive cells are determined by FCM
Redox Biol

p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. [Abstract]

2026 Mar:90:104043. PMID: 41604941
Redox Biol

Heme oxygenase-1 protects cells from replication stress. [Abstract]

2024 Sep:75:103247. PMID: 39047636
Redox Biol

Inhibition of mitochondrial complex I leading to NAD+/NADH imbalance in type 2 diabetic patients who developed late stent thrombosis: Evidence from an integrative analysis of platelet bioenergetics and metabolomics. [Abstract]

2022 Nov:57:102507. PMID: 36244294

Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]

MitoParaquat (0.1 μM, 30 min) abolished the inhibition of platelet aggregation by nicotinamide riboside (1 mM, 30 min) or olaparib (20 μM, 30 min) in resting platelets from LST patients.

Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]

MitoParaquat (0.1 μM, 30 min) did not interrupt the improvements in mitochondrial respiration induced by nicotinamide riboside (1 mM) or olaparib (20 μM) in resting platelets from LST patients.
J Control Release

Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer. [Abstract]

2024 Nov 30:377:661-674. PMID: 39615752
J Control Release

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]

2024 Dec:376:829-841. PMID: 39491626
J Control Release

Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. [Abstract]

2023 May:357:287-298. PMID: 37019285
EBioMedicine

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. [Abstract]

2019 Jun:44:419-430. PMID: 31126889

Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 Jun:44:419-430. [Abstract]

Immunoblots (IB) are done to detect γH2AX and DNA repair proteins, Ku80 and RAD51 using UAB-PA4 or UAB-PA16 tumors harvested from mice 24 h following final treatment. Quantitation by densitometry of results is shown below each IB image.
EBioMedicine

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. [Abstract]

2019 May:43:225-237. PMID: 30898650

Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 May:43:225-237. [Abstract]

Representative images of immunohistochemical staining for proteins as indicated in A2780 xenografted tumors (n=6 per treatment group) treated with Olaparib and PD 0332991 either as single-agents or in combination for 4 days.
MedComm (2020)

Integrated Multi-Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer. [Abstract]

2025 Dec 8;6(12):e70492. PMID: 41377767
J Immunother Cancer

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]

2026 Mar 25;14(3):e012426. PMID: 41881499
Cell Rep Med

HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer. [Abstract]

2026 Feb 18:102630. PMID: 41713410
J Immunother Cancer

The cold immunological landscape of ATM-deficient cancers. [Abstract]

2025 May 11;13(5):e010548. PMID: 40350205
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Pharmacol Res

Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC. [Abstract]

2024 Sep 19:107429. PMID: 39306019
Cell Mol Biol Lett

RSL3 promotes PARP1 apoptotic functions by distinct mechanisms during ferroptosis. [Abstract]

2025 Oct 2;30(1):109. PMID: 41039223
Clin Cancer Res

2021 Feb.
Clin Cancer Res

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. [Abstract]

2019 Oct 15;25(20):6127-6140. PMID: 31409614
Clin Cancer Res

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. [Abstract]

2017 Feb 15;23(4):1001-1011. PMID: 27559053
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556
Cancer Lett

CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer. [Abstract]

2022 Oct 7;551:215944. PMID: 36209974
Cancer Lett

Pentagalloylglucose disrupts the PALB2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy. [Abstract]

2022 Oct 10:546:215851. PMID: 35926819
Cancer Lett

The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma. [Abstract]

2020 Jan 1;468:48-58. PMID: 31605774
Int J Biol Sci

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer. [Abstract]

2024 Aug 19;20(11):4513-4531. PMID: 39247812
Int J Biol Sci

Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis. [Abstract]

2024 Apr 15;20(7):2454-2475. PMID: 38725854
Int J Biol Sci

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. [Abstract]

2020 Feb 21;16(8):1363-1375. PMID: 32210725
Cell Death Dis

KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma. [Abstract]

2024 Dec 6;15(12):882. PMID: 39638799
Cell Death Dis

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. [Abstract]

2022 Sep 27;13(9):826. PMID: 36163324
Cell Death Dis

Loss of tumor suppressor inositol polyphosphate 4-phosphatase type B impairs DNA double-strand break repair by destabilization of DNA tethering protein Rad50. [Abstract]

2020 Apr 27;11(4):292. PMID: 32341333
Cell Death Dis

Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. [Abstract]

2020 Apr 6;11(4):219. PMID: 32249776
Proc Natl Acad Sci U S A

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. [Abstract]

2025 Jun 17;122(24):e2426909122. PMID: 40504161
Proc Natl Acad Sci U S A

The RPA-RNF20-SNF2H cascade promotes proper chromosome segregation and homologous recombination repair. [Abstract]

2023 May 16;120(20):e2303479120. PMID: 37155876
J Pharm Anal

E3 ubiquitin ligase FBXW11-mediated downregulation of S100A11 promotes sensitivity to PARP inhibitor in ovarian cancer. [Abstract]

2025 Jul;15(7):101246. PMID: 40747341
Phytomedicine

2026 Jun 11.
Phytomedicine

Geniposide ameliorates atherosclerosis by restoring lipophagy via suppressing PARP1/PI3K/AKT signaling pathway. [Abstract]

2024 Jul:129:155617. PMID: 38614041
EMBO Mol Med

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. [Abstract]

2023 Mar 8;15(3):e16235. PMID: 36652375
EMBO J

Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death. [Abstract]

2020 Jun 2;39(11):e101573 PMID: 32323871
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086
NPJ Precis Oncol

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer. [Abstract]

2024 Dec 26;8(1):291. PMID: 39725687
NPJ Precis Oncol

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. [Abstract]

2024 Sep 19;8(1):208. PMID: 39294262
NPJ Precis Oncol

ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression. [Abstract]

2023 Jul 10;7(1):66. PMID: 37429899
NPJ Precis Oncol

PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. [Abstract]

2021 Jun 9;5(1):49. PMID: 34108603
Neoplasia

Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. [Abstract]

2025 May:63:101152. PMID: 40096771
Neoplasia

MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. [Abstract]

2025 Feb 11:61:101138. PMID: 39938155
Neoplasia

Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells. [Abstract]

2023 Jul:41:100903. PMID: 37148658
Neoplasia

AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance. [Abstract]

2019 Jul 27;21(9):863-871. PMID: 31362243
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Eur J Nucl Med Mol Imaging

Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. [Abstract]

2024 Nov;51(13):4099-4110. PMID: 39023784
Biomed Pharmacother

Drug target proteome profiling identifies HES1-driven mitotic catastrophe in ovarian serous carcinoma. [Abstract]

2025 Nov 6:193:118716. PMID: 41202420
Biomed Pharmacother

Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway. [Abstract]

2025 Jun 16:189:118273. PMID: 40527032
J Transl Med

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. [Abstract]

2024 Nov 26;22(1):1062. PMID: 39587643
J Transl Med

YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression. [Abstract]

2024 Dec 27;22(1):1153. PMID: 39731187
Biomed Pharmacother

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy. [Abstract]

2024 Nov:180:117485. PMID: 39326103
J Transl Med

ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis. [Abstract]

2024 Feb 21;22(1):192. PMID: 38383406
J Transl Med

PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer. [Abstract]

2023 Jul 6;21(1):445. PMID: 37415147
Biomed Pharmacother

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. [Abstract]

2022 Nov:155:113669. PMID: 36113257
J Transl Med

Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib. [Abstract]

2020 Sep 20;18(1):357. PMID: 32951601
Oncogene

ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer. [Abstract]

2026 Mar 5. PMID: 41786876
Oncogene

SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer. [Abstract]

2025 Nov 28. PMID: 41315667
Oncogene

Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner. [Abstract]

2022 Nov;41(47):5092-5106. PMID: 36245058
Oncogene

A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. [Abstract]

2022 Sep;41(37):4271-4281. PMID: 35933519
Oncogene

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. [Abstract]

2018 Jan 18;37(3):341-351. PMID: 28945226

Olaparib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Jan 18;37(3):341-351. [Abstract]

PTEN-deficient endometrioid endometrial cancer cell lines are treated with drugs as indicated for 24 h. Phosphorylated AKT, S6RP and 4EBP1 proteins and cleaved PARP are detected by western blot. Vinculin served as a loading control.
Aging Cell

Age-Dependent KLK8 Upregulation Contributes to Elevated Susceptibility to Ventilator-Induced Lung Injury in the Elderly Mice. [Abstract]

2026 Jan;25(1):e70304. PMID: 41310943
Blood Adv

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. [Abstract]

2025 Dec 22:bloodadvances.2025016765. PMID: 41428986
Cell Death Discov

ATP2B4 driven chromatin compaction exacerbates pancreatic cancer radiotherapy resistance. [Abstract]

2026 May 25. PMID: 42185253
Cell Death Discov

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors. [Abstract]

2021 Sep 22;7(1):259. PMID: 34552062
Cell Rep

PARP1-specific inhibitor displays PARP1-detrapping activity. [Abstract]

2026 May 4;45(5):117350. PMID: 42090288
Cell Rep

Lactylation-driven nuclear RIG-I promoted by lactate transporter inhibitor suppresses DNA damage repair through inhibiting PARP1 activity. [Abstract]

2026 Jan 13;45(1):116854. PMID: 41538326
Cell Rep

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. [Abstract]

2023 Oct 16;42(10):113256. PMID: 37847590
Cell Rep

C1orf112 teams up with FIGNL1 to facilitate RAD51 filament disassembly and DNA interstrand cross-link repair. [Abstract]

2023 Jul 28;42(8):112907. PMID: 37515771
Cell Rep

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. [Abstract]

2022 Oct 11;41(2):111462. PMID: 36223740

Olaparib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Oct 11;41(2):111462. [Abstract]

With an alternative ROS scavenger, the vitamin E analog Trolox, Olaparib-induced ROS production was similarly suppressed
Cell Rep

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. [Abstract]

2018 Dec 11;25(11):2972-2980.e5. PMID: 30540933
J Med Chem

Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer. [Abstract]

2025 Dec 31. PMID: 41474050
J Med Chem

YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors. [Abstract]

2023 Sep 14;66(17):12284-12303. PMID: 37605459
J Med Chem

A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species. [Abstract]

2020 Sep 10;63(17):9838-9855. PMID: 32809827
Sci Signal

PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells. [Abstract]

2025 Oct 21;18(909):eadx2532. PMID: 41118450
Int J Nanomedicine

Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. [Abstract]

2023 Sep 6:18:5075-5093. PMID: 37701822
Oncogenesis

STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive bladder cancer cells. [Abstract]

2025 Mar 1;14(1):4. PMID: 40025053
Elife

Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor. [Abstract]

2021 Jun 23:10:e69454. PMID: 34159897
Elife

Cohesin mutations are synthetic lethal with stimulation of WNT signaling. [Abstract]

2020 Dec 7;9:e61405. PMID: 33284104
Comput Biol Med

DrugAppy - An end-to-end deep learning framework for computational drug discovery. [Abstract]

2025 Oct 18;198(Pt B):111201. PMID: 41110298
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
JCI Insight

Molecular profiling identifies distinct subtypes across TP53 mutant tumors. [Abstract]

2022 Oct 18;e156485. PMID: 36256461
Hum Reprod

The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. [Abstract]

2020 Aug 1;35(8):1864-1874. PMID: 32604417
Cancer Cell Int

Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer. [Abstract]

2024 Oct 26;24(1):352. PMID: 39462410
Int J Bioprint

2023 Jun 23.
Eur J Med Chem

Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. [Abstract]

2023 Dec 5:261:115858. PMID: 37837671
Eur J Med Chem

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer. [Abstract]

2023 Nov 5:259:115648. PMID: 37478560
Bioeng Transl Med

Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. [Abstract]

2019 Jun 14;4(2):e10131. PMID: 31249881
Biochem Pharmacol

Discovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy. [Abstract]

2025 May:235:116843. PMID: 40024351
Biochem Pharmacol

Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation. [Abstract]

2019 Sep:167:27-32. PMID: 30936015
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
Mol Cancer Ther

FF-10850, a Novel Liposomal Topotecan Achieves Superior Anti-tumor Activity via Macrophage- and Ammonia-mediated Payload Release in the Tumor Microenvironment. [Abstract]

2023 Dec 1;22(12):1454-1464. PMID: 37683276
Mol Cancer Ther

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. [Abstract]

2022 Feb;21(2):245-256. PMID: 34911817
Mol Cancer Ther

ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. [Abstract]

2020 Jan;19(1):282-291. PMID: 31594824
Mol Cancer Ther

PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. [Abstract]

2019 Nov;18(11):2063-2073. PMID: 31413177
Mol Cancer Ther

mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. [Abstract]

2018 Dec;17(12):2676-2688. PMID: 30282812

Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Dec;17(12):2676-2688. [Abstract]

EW8 and TC71 cells are treated with Olaparib (5 μM) or U0126 (5 μM) for 24 hours and then protein synthesis is assessed using puromycin labeling.
Chem Biol Interact

Melatonin suppresses glycolysis and coordinately disrupts DNA repair via targeting the YAP1-NAMPT signaling in breast cancer. [Abstract]

2026 Feb 11:425:111900. PMID: 41485639
Geroscience

The PARP inhibitor olaparib promotes senescence in murine macrophages. [Abstract]

2025 May 6. PMID: 40327273
Mol Ther Oncolytics

lncRNA DUXAP8 Facilitates Multiple Malignant Phenotypes and Resistance to PARP Inhibitor in HCC via Upregulating FOXM1. [Abstract]

2020 Oct 22:19:308-322. PMID: 33313387
J Pathol

PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. [Abstract]

2023 Mar;259(3):318-330. PMID: 36484652
Cells

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. [Abstract]

2019 Oct 15;8(10):1258. PMID: 31619012
Life Sci

PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. [Abstract]

2023 Aug 1:326:121790. PMID: 37211345
Cancer Immunol Immunother

PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures. [Abstract]

2021 Mar;70(3):843-856. PMID: 33492447
Life Sci

Multi-omics analysis of copy number variations of RNA regulatory genes in soft tissue sarcoma. [Abstract]

2021 Jan 15;265:118734. PMID: 33166590
Cancer Gene Ther

Modified hTERT promoters-driven purine nucleoside phosphorylase-gene therapy in association with chemo- and targeted therapy in the context of ovarian cancer. [Abstract]

2025 Aug;32(8):843-853. PMID: 40579465
CNS Neurosci Ther

Olaparib Enhances the Efficacy of Third-Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc-Induced Apoptosis. [Abstract]

2024 Nov;30(11):e70124. PMID: 39552450
Int J Mol Sci

The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma. [Abstract]

2026 Mar 19;27(6):2781. PMID: 41898642
Int J Mol Sci

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell Lines. [Abstract]

2025 Jan 15;26(2):693. PMID: 39859407
Int J Oncol

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. [Abstract]

2022 Nov;61(5):139. PMID: 36169178
J Drug Deliv Sci Technol

27 August 2022, 103731.
Int J Mol Sci

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. [Abstract]

2016 Feb 24;17(3):272. PMID: 26927065

Olaparib purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2016 Feb 24;17(3):272. [Abstract]

The effect of AZD2281 on the protein expression of xenografted HSC-2 tumors. Relative band intensity of western blot data is normalized by the expression level of β-actin; The proteins analyzed are PARP-1 (poly(ADP-ribose) polymerase-1).
Int J Mol Sci

PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway. [Abstract]

2015 Oct 19;16(10):24820-38. PMID: 26492236
Biomolecules

RSL3 Promotes STAT3 Ubiquitination to Induce Autophagy and Apoptosis in PARPi-Resistant Breast Cancer Cells. [Abstract]

2025 Dec 18;15(12):1749. PMID: 41463402
Biomolecules

Inherited Retinal Degeneration: Towards the Development of a Combination Therapy Targeting Histone Deacetylase, Poly (ADP-Ribose) Polymerase, and Calpain. [Abstract]

2023 Mar 23;13(4):581. PMID: 37189329
Cell Oncol (Dordr)

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. [Abstract]

2022 Dec;45(6):1401-1419. PMID: 36269546
Bioorg Chem

A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. [Abstract]

2026 Jun 18:180:110129. PMID: 42348942
J Photochem Photobiol A Chem

2026 Mar 17.
Int Immunopharmacol

CHK1 inhibition by prexasertib sensitizes cisplatin-resistant malignant tumor cells via checkpoint abrogation and STAT1-driven PD-L1 upregulation. [Abstract]

2025 Dec 31:171:116126. PMID: 41477994
Eur J Pharm Sci

Predicting the adsorption behavior of olaparib on zinc oxide nanoparticles for improved pH-responsive drug delivery: experimental and DFT insights. [Abstract]

2025 Sep 2:107253. PMID: 40907898
Int Immunopharmacol

Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis. [Abstract]

2025 Sep 23:162:115158. PMID: 40602265
Eur J Pharmacol

VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]

2025 Sep 15:1003:177942. PMID: 40651787
Int Immunopharmacol

Herkinorin ameliorates neuronal damage in a pentylenetetrazol-induced epilepsy rat model through altering microglial and astrocytic activation by inhibiting PARP1 and NF-κB. [Abstract]

2025 Apr 9:155:114588. PMID: 40209309
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Int J Cancer

PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. [Abstract]

2024 Jul 15;155(2):203-210. PMID: 38619111
Mol Cancer Res

Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition. [Abstract]

2019 Jan;17(1):42-53. PMID: 30201826

Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]

Combination of RAD001 with Olaparib (left panel) and AZD2014 with Olaparib (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.
Eur J Pharmacol

Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells. [Abstract]

2017 Nov 15:815:147-155. PMID: 28887042
RSC Adv

Evaluating the biological characteristics of targeted ZIF-8-encapsulated individual and combined drug systems for enhanced in vivo toxicity mitigation using folic acid ligands. [Abstract]

2026 Jan 6;16(2):1912-1931. PMID: 41503503
Cancer Biol Ther

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway. [Abstract]

2024 Dec 31;25(1):2432117. PMID: 39588922
Mol Pharm

2026 Jun 8.
Mol Oncol

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer. [Abstract]

2025 Jul 13. PMID: 40652528
Cancers (Basel)

Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma. [Abstract]

2024 Nov 5;16(22):3728. PMID: 39594684
Cancers (Basel)

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. [Abstract]

2024 Oct 10;16(20):3441. PMID: 39456536
Cancers (Basel)

Epigenetically Downregulated Breast Cancer Gene 2 through Acetyltransferase Lysine Acetyltransferase 2B Increases the Sensitivity of Colorectal Cancer to Olaparib. [Abstract]

2023 Nov 25;15(23):5580. PMID: 38067284
Cancers (Basel)

HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. [Abstract]

2022 Apr 6;14(7):1848. PMID: 35406624
Cancers (Basel)

Aberrantly Expressed RECQL4 Helicase Supports Proliferation and Drug Resistance of Human Glioma Cells and Glioma Stem Cells. [Abstract]

2020 Oct 11;12(10):2919. PMID: 33050631
FASEB J

Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF-κB/GSDMD Signaling Axis. [Abstract]

2026 Mar 31;40(6):e71636. PMID: 41842655
Ther Adv Med Oncol

The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models. [Abstract]

2025 Apr 21:17:17588359251332471. PMID: 40297621
J Ovarian Res

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy. [Abstract]

2023 Nov 28;16(1):231. PMID: 38017453
Environ Toxicol Pharmacol

Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. [Abstract]

2023 Oct:103:104261. PMID: 37689219
FEBS J

Early loss of endogenous NAD+ following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition. [Abstract]

2023 Mar;290(6):1596-1624. PMID: 36239430
J Cell Mol Med

Altered polymerase theta expression promotes chromosomal instability in salivary adenoid cystic carcinoma. [Abstract]

2022 Jul;26(14):3931-3949. PMID: 35726713
J Cell Mol Med

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. [Abstract]

2020 Feb;24(4):2444-2450. PMID: 31957270
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Cell Mol Med

Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. [Abstract]

2019 Oct;23(10):6797-6804. PMID: 31338966
iScience

Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. [Abstract]

2025 Jun 9;28(7):112860. PMID: 40606759
iScience

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. [Abstract]

2024 Oct 29;27(12):111283. PMID: 39628575
iScience

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. [Abstract]

2024 May 15;27(7):109978. PMID: 39021796
Comput Struct Biotechnol J

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease. [Abstract]

2023 Feb 24:21:1907-1920. PMID: 36936813
Gynecol Oncol

18 August 2021.
Gynecol Oncol

18 August 2021.
Gynecol Oncol

August 2021, Page S288.
Gynecol Oncol

18 August 2021.
Transl Oncol

MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress. [Abstract]

2021 Oct;14(10):101167. PMID: 34280886
Gynecol Oncol

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. [Abstract]

2020 Dec;159(3):827-838. PMID: 32958271
Gynecol Oncol

Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. [Abstract]

2019 Jan;152(1):157-165. PMID: 30414739

Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

The expression of CCND1mRNA and cyclin D1 protein level in A2780 and SKOV3 cells is analyzed by western blot after Olaparib treatment at IC₅₀ concentrations.

Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

Immunohistochemistry for CCND1 is performed in tumor samples in the treatment of compounds (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated).

Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

CCDN1 protein level in tumor samples of different treatment groups (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated) are analyzed by western blot.

Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

Immunohistochemistry of RAD51 and γ-H2AX in samples of SKOV3 tumors. Representative sections are taken from tumor tissue of control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated mice.
Sci Rep

2026 Apr 1.
Sci Rep

PARP-1 couples β-catenin/TCF4 signaling to epithelial-mesenchymal transition in endometriosis. [Abstract]

2026 Feb 2;16(1):6940. PMID: 41629483
Sci Rep

Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies. [Abstract]

2025 Nov 18;15(1):40619. PMID: 41254205
Sci Rep

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. [Abstract]

2023 Feb 27;13(1):3334. PMID: 36849518
Sci Rep

Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells. [Abstract]

2023 Jan 26;13(1):1456. PMID: 36702871
Aging (Albany NY)

Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma. [Abstract]

2021 Nov 27;13(22):24686-24709. PMID: 34837690
Sci Rep

Integrated genomics point to immune vulnerabilities in pleural mesothelioma. [Abstract]

2021 Sep 27;11(1):19138. PMID: 34580349
Sci Rep

Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells. [Abstract]

2020 Oct 13;10(1):17058. PMID: 33051529
Sci Rep

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. [Abstract]

2019 Sep 24;9(1):13786. PMID: 31551480
Oncol Rep

Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer. [Abstract]

2018 Apr;39(4):1747-1756. PMID: 29393493

Olaparib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Apr;39(4):1747-1756. [Abstract]

The effect of Olaparib on protein expression. Western blot assays of MUS81 and MCM2 expression levels in A2780 and SKOV3 cells after treatment with 5 μM Olaparib compared with a blank control.
Microbiol Spectr

Cell type-dependent induction of type I interferon and PARP1 activation in astrocytes and neurons during chikungunya virus infection. [Abstract]

2026 Jun 24:e0417825. PMID: 42370697
J Virol

Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity. [Abstract]

2021 Jul 26;95(16):e0076021. PMID: 34037418
Hum Mutat

E2F4 Mediates Mitophagy to Inhibit Ferroptosis in Esophageal Cancer Cells by Activating GPR176. [Abstract]

2026 May 30:2026:9418012. PMID: 42253509
Cell Signal

Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer. [Abstract]

2025 Dec 16:112328. PMID: 41412562
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Cell Signal

Activated PARP1/FAK/COL5A1 signaling facilitates the tumorigenesis of cholesterol-resistant ovarian cancer cells through promoting EMT. [Abstract]

2024 Sep 16:111419. PMID: 39293744
ACS Pharmacol Transl Sci

Inhibition of Protein Disulfide Isomerase (PDIA1) Leads to Proteasome-Mediated Degradation of Ubiquitin-like PHD and RING Finger Domain-Containing Protein 1 (UHRF1) and Increased Sensitivity of Glioblastoma Cells to Topoisomerase II Inhibitors. [Abstract]

2022 Dec 7;6(1):100-114. PMID: 36654750
J Proteome Res

Multiomics Insights into the Mechanism and Enhanced Efficacy of Tumor Treating Fields (TTFields) Therapy in Glioblastoma. [Abstract]

2025 Oct 3;24(10):5056-5070. PMID: 40889189
Heliyon

Danlou tablet alleviates sepsis-induced acute lung and kidney injury by inhibiting the PARP1/HMGB1 pathway. [Abstract]

2024 Apr 23;10(9):e30172. PMID: 38707378
J Cell Sci

Non-canonical regulation of homologous recombination DNA repair by the USP9X deubiquitylase. [Abstract]

2020 Feb 12;133(3):jcs233437. PMID: 31964704
Viruses

Role of PARP-1 in Human Cytomegalovirus Infection and Functional Partners Encoded by This Virus. [Abstract]

2022 Sep 15;14(9):2049. PMID: 36146855
Mol Med Rep

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. [Abstract]

2021 Aug;24(2):548. PMID: 34080025
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
BMC Cancer

Shared and non-overlapping functions of RECQL4 and BLM helicases in chemotherapeutics-induced glioma cell responses. [Abstract]

2025 Sep 29;25(1):1434. PMID: 41023983
BMC Cancer

Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma. [Abstract]

2024 Dec 20;24(1):1562. PMID: 39707244
BMC Cancer

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. [Abstract]

2022 Mar 23;22(1):312. PMID: 35321693
Analyst

Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment. [Abstract]

2026 Mar 5. PMID: 41784206
Front Oncol

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [Abstract]

2021 Jul 9:11:681441. PMID: 34307148
Int J Med Sci

NDUFS1 upregulates ENaCα by NAD+ to promote alveolar fluid clearance in acute lung injury. [Abstract]

2025 Jul 28;22(13):3477-3489. PMID: 40860777
Epigenetics

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells. [Abstract]

2024 Dec;19(1):2357518. PMID: 38796857
J Cancer

Targeting NEAT1 Affects the Sensitivity to PARPi in Serous Ovarian Cancer by Regulating the Homologous Recombination Repair Pathway. [Abstract]

2024 Jan 20;15(5):1397-1413. PMID: 38356722
J Cancer

Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. [Abstract]

2022 Apr 11;13(7):2226-2237. PMID: 35517402
Cell Biol Int

Lactate Prevents Glucose Deprivation-Induced Parthanatos in Gastric Cancer Cells Through Alleviating Intracellular Reactive Oxygen Species. [Abstract]

2025 Jul 31. PMID: 40745690
Hum Cell

Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma. [Abstract]

2025 Jul 7;38(5):125. PMID: 40624380
Naunyn Schmiedebergs Arch Pharmacol

Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study. [Abstract]

2023 Jul;396(7):1435-1450. PMID: 36738368
J Pharm Biomed Anal

Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products. [Abstract]

2018 Oct 25:160:89-98. PMID: 30075398
EJNMMI Res

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [Abstract]

2025 Apr 29;15(1):50. PMID: 40301197
Bioorg Med Chem

Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor. [Abstract]

2024 Oct 26:115:117970. PMID: 39476572
Discov Oncol

CDCA5 knockdown potentiates olaparib sensitivity in BRCA1-mutated ovarian cancer through autophagy activation. [Abstract]

2025 Sep 30;16(1):1789. PMID: 41026320
Am J Cancer Res

TNKS inhibitors potentiate proliferative inhibition of BET inhibitors via reducing β-Catenin in colorectal cancer cells. [Abstract]

2022 Mar 15;12(3):1069-1087. PMID: 35411247
Am J Cancer Res

CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. [Abstract]

2020 Apr 1;10(4):1140-1155. PMID: 32368391
J Cancer Res Clin Oncol

Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations. [Abstract]

2025 Mar 26;151(3):124. PMID: 40138020
J Biochem Mol Toxicol

SALL4/ABCB6 Axis Suppresses Ferroptosis in Colon Cancer by Mediating Mitophagy. [Abstract]

2025 Mar;39(3):e70183. PMID: 40052371
Onco Targets Ther

Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib. [Abstract]

2023 Dec 19:16:1061-1071. PMID: 38144904
J Anal Sci Technol

2023 Aug 9.
Invest New Drugs

Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells. [Abstract]

2025 Aug 4. PMID: 40760233
DNA Repair

DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors. [Abstract]

2024 Jul:139:103689. PMID: 38749239
Invest New Drugs

Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. [Abstract]

2021 Oct;39(5):1213-1221. PMID: 33710464
DNA Repair

PML nuclear bodies are recruited to persistent DNA damage lesions in an RNF168-53BP1 dependent manner and contribute to DNA repair. [Abstract]

2019 Jun:78:114-127. PMID: 31009828
DNA Repair

Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors. [Abstract]

2019 Jan:73:64-70. PMID: 30470508
New J Chem

2025.
Biomed Res Int

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]

2023 Feb 6:2023:7891753. PMID: 36794257
Cancer Chemother Pharmacol

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. [Abstract]

2017 Oct;80(4):861-867. PMID: 28756516

Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867. [Abstract]

PARP1 inhibition is lethal to MPM cells. Colony formation assays of clonal cell survival with continuous Niraparib or Olaparib, both at 3 uM. a H2452 BPA1-mutant MPM cells exposed to Niraparib. b HMeso01A BAP1-mutant MPM cells exposed to Niraparib. cHMeso01A BAP1-mutant MPM cells exposed to Olaparib. d CRL-2081 BAP1 wild-type MPM cells exposed to Olaparib. e CRL-2081 BAP1 wild-type MPM cells exposed to Niraparib. f Dose response of H2452 BPA1-mutant MPM cells exposed to varying concentrations of
Biochem Biophys Res Commun

Genomic and immune landscape of parthanatos in breast carcinoma: The central role of AIFM1. [Abstract]

2026 Feb 12:800:153283. PMID: 41534495
Biochem Biophys Rep

Bifendate inhibits cell PARthanatos by activating the MEK/ERK pathway. [Abstract]

2026 Jan 15:45:102454. PMID: 41584303
Oncol Lett

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]

2025 Jan 7;29(3):128. PMID: 39822940
Cancer Genet

A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents. [Abstract]

2019 Nov:239:26-32. PMID: 31476665
Biol Pharm Bull

Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia-Reoxygenation. [Abstract]

2019 May 1;42(5):721-727. PMID: 30867343
Biomed Chromatogr

Pharmacokinetics and metabolism of LNP023 in rats by liquid chromatography combined with electrospray ionization-tandem mass spectrometry. [Abstract]

2021 Mar;35(3):e5006. PMID: 33067853
Biomed Chromatogr

A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. [Abstract]

2021 Feb;35(2):e4968. PMID: 32881002
Ir J Med Sci

Resveratrol potentiates chemotherapeutic efficacy of olaparib in MCF7 human breast cancer cells by inducing apoptosis. [Abstract]

2026 Jan 10. PMID: 41518560
J Pancreatol

2023 Dec 12.
J Mens Health

2024 Mar 30.
bioRxiv

2026 Jun 25.
Res Sq

2026 Jun 17.
bioRxiv

2026 Jun 26.
bioRxiv

2026 Jun 19.
bioRxiv

2026 May 11.
Duke University

2026.
Res Connect

2026 May 28.
Res Sq

2026 May 20.
SSRN

2026 Apr 9.
SSRN

2026 Apr 1.
bioRxiv

PARP16 is a Druggable Regulator of Ribosome MARylation and Protein Homeostasis in Ovarian Cancer Cells. [Abstract]

2026 Apr 2:2026.04.01.715986. PMID: 41959139
Res Sq

2026 Mar 5.
bioRxiv

2026 Mar 5.
bioRxiv

2026 Mar 18.
bioRxiv

2026 Jan 13.
Res Sq

2026 Jan 9.
bioRxiv

2025 Dec 12.
bioRxiv

2025 Dec 25.
bioRxiv

2025 Nov 6.
bioRxiv

Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. [Abstract]

2025 Nov 4:2025.11.03.686423. PMID: 41278667
Res Sq

PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity. [Abstract]

2025 Nov 7:rs.3.rs-7881707. PMID: 41282221
bioRxiv

2025 Nov 6.
bioRxiv

2025 Oct 22.
bioRxiv

IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer. [Abstract]

2025 Oct 15:2025.10.14.682312. PMID: 41279612
bioRxiv

Xenophagocytosis blockade enhances interspecies chimerism. [Abstract]

2025 Oct 15:2025.10.14.682291. PMID: 41279269
SSRN

2025 Oct 13.
bioRxiv

Loss of CFIm activates YAP/TAZ and connects mRNA cleavage and polyadenylation inhibition to BRCAness. [Abstract]

2025 Oct 21:2025.10.21.683728. PMID: 41278918
bioRxiv

2025 Sep 29.
Patent

US20250268827A1.
SSRN

2025 Sep 26.
bioRxiv

2025 Aug 31.
Patent

US20250288582A1.
bioRxiv

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells. [Abstract]

2025 Sep 30:2025.09.30.679484. PMID: 41256515
bioRxiv

2025 Sep 21.
University of Arizona

2025.
University of Califomia San Francisco

2025.
University of California

2025.
Res Sq

2025 Apr 15.
bioRxiv

2025 April 17.
bioRxiv

2025 March 14.
bioRxiv

TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. [Abstract]

2025 Jan 27:2025.01.26.634889. PMID: 39975297
bioRxiv

2025 January 14.
Patent

US20240252689A1
bioRxiv

2024 November 06.
bioRxiv

2024 September 13.
bioRxiv

PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]

2024 Nov 6:2024.11.04.621884. PMID: 39574568
Res Sq

2024 Sep 08.
bioRxiv

All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer. [Abstract]

2024 Oct 23:2024.10.20.619300. PMID: 39484589
bioRxiv

2024 September 13.
bioRxiv

Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection. [Abstract]

2024 Sep 19:2024.09.19.613696. PMID: 39345583
Res Sq

2024 Jun 13.
bioRxiv

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. [Abstract]

2024 Jul 10:2024.07.09.602803. PMID: 39026842
bioRxiv

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. [Abstract]

2024 Jul 12:2024.07.10.602941. PMID: 39026771
University of British Columbia

2024 Apr 30.
bioRxiv

2024 Mar 29.
Res Sq

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency. [Abstract]

2024 Apr 1:rs.3.rs-3995251. PMID: 38645014
Research Square Preprint

2024 Feb 7.
Research Square Preprint

2024 Jan 24.
Research Square Preprint

2023 Dec 27
bioRxiv

2023 Aug 15.
University of Ottawa

2023 Jun 12.
Research Square Preprint

2023 May 30.
University of Gothenburg

2023 Jun 27.
Research Square Preprint

2023 Jun 9.
bioRxiv

Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. [Abstract]

2023 Jun 14:2023.06.13.544756. PMID: 37398283
Res Sq

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. [Abstract]

2023 Apr 6:rs.3.rs-2688694. PMID: 37066268
Universidad de Granada

2023 Mar 27.
bioRxiv

2023 Apr 17.
bioRxiv

A PARP inhibitor, rucaparib, improves cardiac dysfunction in ADP-ribose-acceptor hydrolase 3 ( Arh3 ) deficiency. [Abstract]

2023 Feb 7:2023.02.07.527369. PMID: 36945462
Patent

US20230042929A1.
Democritus University of Thrace

2022.
Methods Mol Biol

Quantification of PARP7 Protein Levels and PARP7 Inhibitor Target Engagement in Cells Using a Split Nanoluciferase System. [Abstract]

2023:2609:387-395. PMID: 36515849
Oxid Med Cell Longev

PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/ β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib. [Abstract]

2022 Sep 5:2022:9029544. PMID: 36105480
J Pers Med

Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. [Abstract]

2022 Aug 1;12(8):1270. PMID: 36013219
Patent

US20220177954A1.
Seoul National University

Molecular medicine and Biopharmaceutical sciences. 2021 Dec.
Univerzita Karlova v Praz

2021 Nov.
J Pers Med

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer. [Abstract]

2021 Oct 8;11(10):1009. PMID: 34683150
University of London

2021 Sep.
Oxid Med Cell Longev

Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells. [Abstract]

2021 Sep 14:2021:7308897. PMID: 34567413
Oncotarget

Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1. [Abstract]

2021 Mar 30;12(7):649-664. PMID: 33868586
Research Square Preprint

2021 Feb.
bioRxiv

2021 Jan 27.
Patent

US20200289554A1.
University of Michigan

2020 Oct.
Patent

US20200268864A1.
Research Square Preprint

2020 Sep.
Oncotarget

Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. [Abstract]

2020 May 5;11(18):1653-1665. PMID: 32405340
Patent

US20200129476A1
bioRxiv

2020 Mar.
Patent

US20200078369A1
medRxiv

2020 Jan.
Patent

US20180362972A1.
Patent

US20180263995A1.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (230.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3017 mL

11.5085 mL

23.0171 mL

5 mM

0.4603 mL

2.3017 mL

4.6034 mL

10 mM

0.2302 mL

1.1509 mL

2.3017 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (11.51 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (11.51 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (11.51 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

This assay determined the ability of Olaparib to inhibit PARP-1 enzyme activity. PARP-2 activity inhibition is measured by using a variation of the PARP-1 assay in which PARP-2 protein (recombinant) is bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity is measured following ³H-NAD⁺ DNA additions. After washing, scintillant is added to measure ³H-incorporated ribosylations. For tankyrase-1, an AlphaScreen assay is developed in which HIS-tagged recombinant TANK-1 protein is incubated with biotinylated NAD⁺ in a 384-well ProxiPlate assay. Alpha beads are added to bind the HIS and biotin tags to create a proximity signal, whereas the inhibition of TANK-1 activity is directly proportional to the loss of this signal. All experiments are repeated at least three times^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

The PF₅₀ value is the potentiation factor, which is calculated as the ratio of the IC₅₀ of the control growth with alkylating agent methylmethane sulfonate (MMS) divided by the IC₅₀ of the MMS combined with the PARP inhibitor. HeLa B cells are used, and Olaparib is tested at a fixed 200 nM concentration for screening with MMS. For the testing of Olaparib on the SW620 colorectal cell line, the concentrations that are used are 1, 3, 10, 100 and 300 nM. Cell growth is assessed by the use of the sulforhodamine B (SRB) assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Mice bearing 220-250 mm³ tumors are randomized into 4 treatment groups (n=5): A; vehicle control (10% DMSO in PBS/10% 2-hydroxy-propyl-β-cyclodextrin daily for 5 days by oral gavage), B; Olaparib (50 mg/kg daily for 5 days by oral gavage), C; 10 Gy fractionated radiotherapy (2 Gy daily for 5 days), D; Olaparib and 10 Gy (5×2 Gy) fractionated radiotherapy (with olaparib given 30 min prior to each daily 2 Gy dose of radiation). Tumor volume measurements are determined daily until they reached 1000 mm³. The number of days for each individual tumor to quadruple in size from the start of the treatment (relative tumor volume×4; RTV4) is calculated for the individual tumors in each group.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (584 KB)
- English - EN (584 KB)
- Français - FR (584 KB)
- Deutsch - DE (584 KB)
- Norwegian - NO (584 KB)
- Español - ES (584 KB)
- Swedish - SV (584 KB)
- Italian - IT (584 KB)
- Korean - KR (584 KB)
- Portuguese - PT (584 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91 [Content Brief]

[2]. Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10(10):1949-58. [Content Brief]

[3]. Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17(3):272. [Content Brief]

[4]. Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3017 mL	11.5085 mL	23.0171 mL	57.5427 mL
	5 mM	0.4603 mL	2.3017 mL	4.6034 mL	11.5085 mL
	10 mM	0.2302 mL	1.1509 mL	2.3017 mL	5.7543 mL
	15 mM	0.1534 mL	0.7672 mL	1.5345 mL	3.8362 mL
	20 mM	0.1151 mL	0.5754 mL	1.1509 mL	2.8771 mL
	25 mM	0.0921 mL	0.4603 mL	0.9207 mL	2.3017 mL
	30 mM	0.0767 mL	0.3836 mL	0.7672 mL	1.9181 mL
	40 mM	0.0575 mL	0.2877 mL	0.5754 mL	1.4386 mL
	50 mM	0.0460 mL	0.2302 mL	0.4603 mL	1.1509 mL
	60 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9590 mL
	80 mM	0.0288 mL	0.1439 mL	0.2877 mL	0.7193 mL
	100 mM	0.0230 mL	0.1151 mL	0.2302 mL	0.5754 mL

Keywords

Olaparib

375 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Olaparib

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Olaparib

Voir tous les produits spécifiques à Isoform PARP

Activité biologique

Chemical Information

Publications (375)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Olaparib Related Classifications

HY-10162 Related Classifications